Skip to main content
. 2015 May 29;29(9):1152–1155. doi: 10.1038/eye.2015.87

Table 2. Visual and anatomic characteristics (n=21 eyes).

  Baseline following previous ranibizumab/bevacizumab 24-month post transition to aflibercept P-valuea
Mean BCVA (logMAR) 0.42±0.31 0.42±0.23 0.20
Mean OCT CFT (microns) 292.1±83.2 283.6±78.6 0.40
Mean OCT MV (mm3) 7.9±0.95 7.67±0.94 0.16
Mean treatment interval (days) 37.0 59.3 0.01

Abbreviations: BCVA, best-corrected visual acuity; CFT, central subfoveal thickness; MV, macular volume.

a

Paired t-test; data presented as mean±SD.